Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Reiss

Showing results (391-400 of 509) with videos related to

Pageof 51
Sort By:
Antiviral Therapy|December 1, 2005
Predictors of hypertension and changes of blood pressure in HIV-infected patientsRodolphe Thiébaut, Wafaa M El-Sadr, Nina Friis-Møller, et al.
Journal of the International AIDS Society|August 9, 2024
Assessing the HIV care continuum among transgender women during 11 years of follow-up: results from the Netherlands' ATHENA observational cohortVita W Jongen, Ceranza Daans, Ard van Sighem, et al.
Lancet (London, England)|April 5, 2008
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Caroline A Sabin, Signe W Worm, et al.
The Journal of Infectious Diseases|July 9, 2020
The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D StudyLene Ryom, Jens D Lundgren, Peter Reiss, et al.
Nature Communications|April 22, 2025
Model-based evaluation of the impact of a potential HIV cure on HIV transmission dynamicsAlfredo De Bellis, Myrthe S Willemsen, Giorgio Guzzetta, et al.
The New England Journal of Medicine|November 25, 2003
Combination antiretroviral therapy and the risk of myocardial infarctionNina Friis-Møller, Caroline A Sabin, Rainer Weber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2016
Difference in Aortic Stiffness Between Treated Middle-Aged HIV Type 1-Infected and Uninfected Individuals Largely Explained by Traditional Cardiovascular Risk Factors, With an Additional Contribution of Prior Advanced ImmunodeficiencyKatherine W Kooij, Judith Schouten, Ferdinand W N M Wit, et al.
AIDS (London, England)|February 1, 2024
Specific plasma microRNAs are associated with CD4 + T-cell recovery during suppressive antiretroviral therapy for HIV-1Stefanie Kroeze, Neeltje A Kootstra, Ad C van Nuenen, et al.
The Lancet. HIV|November 2, 2015
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trialJose I Bernardino, Amanda Mocroft, Patrick W Mallon, et al.
Plos Medicine|November 5, 2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Frank van Leth, Prahpan Phanuphak, Erik Stroes, et al.
Pageof 51

Showing results (391-400 of 509) with videos related to

Sort By:
Pageof 51
Antiviral Therapy|December 1, 2005
Predictors of hypertension and changes of blood pressure in HIV-infected patientsRodolphe Thiébaut, Wafaa M El-Sadr, Nina Friis-Møller, et al.
Journal of the International AIDS Society|August 9, 2024
Assessing the HIV care continuum among transgender women during 11 years of follow-up: results from the Netherlands' ATHENA observational cohortVita W Jongen, Ceranza Daans, Ard van Sighem, et al.
Lancet (London, England)|April 5, 2008
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Caroline A Sabin, Signe W Worm, et al.
The Journal of Infectious Diseases|July 9, 2020
The Impact of Immunosuppression on Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: The D:A:D StudyLene Ryom, Jens D Lundgren, Peter Reiss, et al.
Nature Communications|April 22, 2025
Model-based evaluation of the impact of a potential HIV cure on HIV transmission dynamicsAlfredo De Bellis, Myrthe S Willemsen, Giorgio Guzzetta, et al.
The New England Journal of Medicine|November 25, 2003
Combination antiretroviral therapy and the risk of myocardial infarctionNina Friis-Møller, Caroline A Sabin, Rainer Weber, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 12, 2016
Difference in Aortic Stiffness Between Treated Middle-Aged HIV Type 1-Infected and Uninfected Individuals Largely Explained by Traditional Cardiovascular Risk Factors, With an Additional Contribution of Prior Advanced ImmunodeficiencyKatherine W Kooij, Judith Schouten, Ferdinand W N M Wit, et al.
AIDS (London, England)|February 1, 2024
Specific plasma microRNAs are associated with CD4 + T-cell recovery during suppressive antiretroviral therapy for HIV-1Stefanie Kroeze, Neeltje A Kootstra, Ad C van Nuenen, et al.
The Lancet. HIV|November 2, 2015
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trialJose I Bernardino, Amanda Mocroft, Patrick W Mallon, et al.
Plos Medicine|November 5, 2004
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1Frank van Leth, Prahpan Phanuphak, Erik Stroes, et al.
Pageof 51